Physician profile
Eric B Geller
NPI 1780788992
$5,967.55
in general payments reported to CMS, 2019-2025
30 companies · $453 in 2025
The $453 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,329 · 2020: $2,936 · 2021: $305 · 2022: $305 · 2023: $221 · 2024: $419 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,093.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,093.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuropace, INC. | $4,150.32 | 2019-2023 | |
| Abbvie INC. | $247.18 | 2022-2025 | |
| Livanova USA, INC. | $209.86 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Sk Life Science, INC. | $174.60 | 2021-2024 | |
| Amgen INC. | $140.28 | 2021-2025 | Uplizna |
| Novartis Pharmaceuticals Corporation | $91.24 | 2019-2021 | |
| Pfizer INC. | $90.62 | 2024-2025 | |
| Corium, LLC | $86.62 | 2024 | Azstarys |
| Ucb, INC. | $77.00 | 2023-2025 | Briviact, Fintepla, Nayzilam |
| Pyros Pharmaceuticals, INC. | $65.26 | 2024 | Vigpoder |
| Harmony Biosciences LLC | $61.99 | 2020-2024 | |
| Aquestive Therapeutics, INC. | $58.90 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $57.99 | 2021-2025 | Qelbree |
| Jazz Pharmaceuticals INC. | $51.55 | 2019-2025 | |
| Medtronic USA, INC. | $45.80 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $43.27 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $42.27 | 2019-2021 | |
| Aucta Pharmaceuticals, INC. | $39.45 | 2024 | Motpoly Xr |
| Immedica Pharma US, INC. | $29.59 | 2023 | |
| Ironshore Pharmaceuticals INC. | $29.32 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $26.19 | 2023 | Daybue |
| Lilly USA, LLC | $25.86 | 2019-2021 | |
| Avadel Cns Pharmaceuticals, LLC | $18.40 | 2025 | Lumryz |
| Nobelpharma America, LLC | $17.37 | 2024 | |
| Arbor Pharmaceuticals, INC. | $16.64 | 2022 | |
| Eisai INC. | $15.26 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.00 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $14.06 | 2021 | |
| Genzyme Corporation | $13.80 | 2020 | |
| Greenwich Biosciences, INC. | $11.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Geller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.